Literature DB >> 27658814

Infliximab biosimilars are safe, effective, and cheap, UK audit shows.

Caroline White1.   

Abstract

Year:  2016        PMID： 27658814     DOI： 10.1136/bmj.i5084

Source DB:  PubMed          Journal:  BMJ        ISSN： 0959-8138


× No keyword cloud information.
  2 in total

1.  Market share and costs of biologic therapies for inflammatory bowel disease in the USA.

Authors:  H Yu; D MacIsaac; J J Wong; Z M Sellers; A A Wren; R Bensen; C Kin; K T Park
Journal:  Aliment Pharmacol Ther       Date:  2017-11-22       Impact factor: 8.171

2.  Clinical outcomes, predictors of prognosis and health economics consequences in IBD patients after discontinuation of the first biological therapy.

Authors:  Uday N Shivaji; Alina Bazarova; Tamsin Critchlow; Samuel C L Smith; Olga Maria Nardone; Melanie Love; Joanne Davis; Subrata Ghosh; Marietta Iacucci
Journal:  Therap Adv Gastroenterol       Date:  2020-12-27       Impact factor: 4.409
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.